Zogenix — Corporate Update (November 2014)
23 slides from Zogenix's corporate update, Nov 18, 2014
Slide 1: Company Update
Exhibit 99.1 NASDAQ: Company Update November 2014
Slide 2: Forward Looking Statement
Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming,
Slide 3: Developing and Commercializing High Value CNS Products
Developing and Commercializing High Value CNS Products CHRONIC PAIN DRAVET SYNDROME SCHIZOPHRENIA (low-dose fenfluramine) Oral, 12-Hour Dravet syndrome Subcutaneous Extended Release Product Candidate With Once-Monthly Hydrocodone without Long-Term Data Antipsychotic Acetaminophen $16B Market Orphan
Slide 4: CNS Pipeline – Innovative Development and Regulatory Timelines
CNS Pipeline – Innovative Development and Regulatory Timelines 4
Slide 5: Oral, Extended Release Hydrocodone Acetaminophen-Free
Oral, Extended Release Hydrocodone Acetaminophen -Free Hydrocodone Product FDA Approved Launched October 2013 March 2014 5
Slide 6: Zohydro ER Commercial Update
Zohydro ER Commercial Update • 15,134 Prescriptions in 3Q 2014, up 47% over 2Q 2014 METRICS • 31,000 Prescriptions and 4000 Prescribers from Launch Through October 24, 2014 • 8 out of 10 Prescriptions Approved by Payers • Average NSP $240 • >7000 Pharmacies Stocking Zohydro ER • sNDA for modified fo
Slide 7: Zohydro ER Fills an Important Medical Need
Zohydro ER Fills an Important Medical Need • About 5% of patients on hydrocodone combination products are using it to manage chronic pain – Unintentional acetaminophen overdose* is the leading cause of acute liver failure – No extended-release version of hydrocodone had been available • Zohydro ER i
Slide 8: Zogenix Commitment to Responsible Commercialization
Zogenix Commitment to Responsible Commercialization SaferLock ™ Locking Bottle for safe storage ADF • Abuse Deterrent Formulations STORAGE • Distribution of Safe Storage Mechanisms MONITORING • Surveillance and Monitoring to Detect Potential Misuse, Abuse and Diversion SALES • Certification of Zogen
Slide 9: Two Abuse Deterrent Formulations In Development
Abuse Deterrent (AD) Formulations In Development • Addition of Inert Beads That Form a Viscous Gel When Crushed and Dissolved in Aqueous Solvents Modification of – Designed to be injection and insufflation resistant Approved Capsule • Supplemental Application to Approved NDA Formulation – Formulatio
Slide 10: Brabafen
BRABAFEN ™ Low-dose fenfluramine for the treatment of Dravet syndrome, a rare and catastrophic form of intractable epilepsy that begins in infancy Phase 3 Candidate Orphan drug designation in Europe and U.S. 10
Slide 11: Brabant Pharma Acquisition
Brabant Pharma Acquisition • Acquired October 27, 2014 for $20 million in cash and $15 million in stock plus potential future milestone and royalty payments • Worldwidedevelopmentandcommercializationrightsto BrabafenTM, low- dose fenfluramine, for the treatment of Dravet syndrome, a rare and catastr
Slide 12: Dravet Syndrome – Rare And Severe Condition
Dravet Syndrome – Rare And Severe Condition • Orphan disease with incidence between 1:20,000 and 1:40,000 births live • Genetic condition associated with mutations of the SCN1A gene – Severe, frequent seizures; drug-refractory – Cognitive decline; increasing motor problems – Children do not outgrow
Slide 13: Long Term Results of Brabafen In Dravet Syndrome Showed Significant Reduction in Seizures (n=15)
Long Term Results of Brabafen In Dravet Syndrome Showed Significant Reduction in Seizures (n=15) • Average length of treatment >12 years; Brabafen Responder Analysis longest duration = 26 years 100% – Mean age at last evaluation = 19 yr (3-35 yr) 93% 93% N=14 N=14 87% • Fenfluramine (5-10 mg BID) ad
Slide 14: Remaining Development Plan for Brabafen
Remaining Development Plan for Brabafen • Agreed upon pre-clinical and clinical requirements from FDA and EMA • Phase 3 pivotal clinical study protocol – Two placebo controlled studies (United States and Europe) – 40-60 patients each – Add-on therapy – 12-week evaluation period – Evaluating number o
Slide 15: Once-Monthly Risperidone for Schizophrenia (Relday)
Once-Monthly Risperidone With A Unique PK Profile, Available as a Subcutaneous Injection for Treatment of Schizophrenia Phase 1b J –an 2015 Proof of Concept Established 15
Slide 16: Long Acting Injections (LAIs): A Highly Attractive Market
Long Acting Injections (LAIs): A Highly Attractive Market Further Clinical Evidence of Earlier LAI Usage Will Likely Drive Additional Upside U.S. LAI Sales (Schizophrenia) $2.8 Billion Market $ Millions in U.S.+ Europe in 2013 • Highly Concentrated U.S. Market with $1.2B 11,000 Psychiatrists Prescri
Slide 17: RELDAY Product Profile vs. Current LAI Atypical Antipsychotics (AA)
RELDAY Product Profile vs. Current LAI Atypical Antipsychotics (AA) KEY ATTRIBUTES RISPERDAL INVEGA ZYPREXA ABILIFY FROM PHYSICIAN CONSTA SUSTENNA RELPREVV MAINTENA RELDAY RESEARCH (RISPERIDONE) (PALIPERIDONE) (OLANZAPINE) (ARIPIPRAZOLE) (RISPERIDONE) Therapeutic Levels on Day 1 No Loading Dose/ Ora
Slide 18: RELDAY Clinical Program Status
RELDAY Clinical Program Status REGULATORY • Confirmed 505(b)(2) NDA in US STRATEGY • Abridged Hybrid MAA likely in EU PROOF OF • Established in the First IND Study CONCEPT • Subjects with Schizophrenia (n=40) • Pharmacokinetics (PK) – Therapeutic Levels within 8 hours of Dosing – First Day Levels Co
Slide 19: RELDAY Clinical Study Design
RELDAY Clinical Study Design OVERVIEW • Open-Label, PK and Safety, in Patients with Chronic, Stable Schizophrenia or Schizoaffective Disorder (n=40) • Patients Randomizedinto One of FourCohorts: – Cohort 1: Relday, 60mg Once-Monthly SQ Depot Injection – Cohort 2: Relday, 90mg Once-Monthly SQ Depot I
Slide 20: Financial Highlights
Financial Highlights Q3 2014 Total Revenue $8.8M (Zohydro ER revenue of $4.1M) Market Capitalization $190M (8-6-14 ~139,539,151 Shares) $50.5M Q3 2014 Cash Balance (1) and $8.5M(escrow) Debt(2) $0M Common Stock Outstanding 153,040,066 Fully Diluted Shares (3) 185,657,387 Employees 220 (1) Excludes $
Slide 21: Experienced Management Team
Experienced Management Team INDUSTRY EXPERIENCE Roger Hawley Chief Executive Officer 27 Glaxo, GSK, Elan, InterMune Co-Founder Stephen Farr, Ph.D. President 21 Aradigm, Cardiff University Co-Founder Ann Rhoads 20 Premier, Sprout, DLJ, Bain & Co, Merrill Lynch Chief Financial Officer Bradley Galer, M
Slide 22: Significant Cadence of Potential Value Creating Milestones Through 2018
Significant Cadence of Potential Value Creating Milestones Through 2018 Relday Multi-Dose Clinical Trial Begins Abuse Liability Studies Zohydro ER AD capsules Begins sNDA Potential Approval Zohydro ER (AD capsules) 2015 Potential Zohydro ER Co-Promotion Brabafen Phase 3 Clinical Trial Begins Relday
Slide 23: Logeni#
Logeni#